Sanofi $SNY Holdings Increased by Managed Asset Portfolios LLC

Managed Asset Portfolios LLC increased its stake in shares of Sanofi (NASDAQ:SNY) by 0.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 608,999 shares of the company’s stock after acquiring an additional 5,458 shares during the period. Sanofi comprises 3.8% of Managed Asset Portfolios LLC’s holdings, making the stock its 7th largest position. Managed Asset Portfolios LLC’s holdings in Sanofi were worth $29,421,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of SNY. Ameritas Advisory Services LLC acquired a new stake in shares of Sanofi during the 2nd quarter worth approximately $28,000. Accent Capital Management LLC purchased a new stake in Sanofi during the first quarter worth $29,000. Eastern Bank grew its position in Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after buying an additional 300 shares during the period. Banque Transatlantique SA purchased a new position in Sanofi in the first quarter valued at $33,000. Finally, Brentview Investment Management LLC acquired a new position in shares of Sanofi in the first quarter worth about $42,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently commented on SNY. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research note on Tuesday, November 11th. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Finally, Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $62.67.

Sanofi Stock Performance

Shares of NASDAQ:SNY opened at $50.66 on Wednesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.94. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The firm has a market capitalization of $124.40 billion, a PE ratio of 11.86, a P/E/G ratio of 1.38 and a beta of 0.49. The business’s 50 day moving average price is $49.16 and its 200-day moving average price is $49.35.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 24th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.60 by $0.10. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The firm had revenue of $14.53 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same period in the prior year, the company earned $2.25 EPS. The firm’s revenue was down 7.5% compared to the same quarter last year. As a group, equities research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.